{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/fr\/","title":"Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"PnbuH7jc9K\"><a href=\"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/\">Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-2\/embed\/#?secret=PnbuH7jc9K\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Un traitement prometteur pour ceux qui ne tol\u00e8rent pas les statines et dont la concentration de C-LDL est tr\u00e8s \u00e9lev\u00e9e\u00a0\u00bb &#8212; The Medical Xchange\" data-secret=\"PnbuH7jc9K\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7009_AHA_LBCT_Odyssey_fr_fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Chicago \u2013 L\u2019essai ODYSSEY ALTERNATIVE a r\u00e9v\u00e9l\u00e9 qu\u2019au bout de 24 semaines de traitement, un inhibiteur de la PCSK9 avait abaiss\u00e9 les concentrations de cholest\u00e9rol des LDL (C-LDL) de fa\u00e7on significativement plus prononc\u00e9e qu\u2019un inhibiteur de l\u2019absorption du cholest\u00e9rol chez des patients ne tol\u00e9rant pas les statines et dont les concentrations \u00e9taient au d\u00e9part tr\u00e8s \u00e9lev\u00e9es. L\u2019inhibiteur de la PCSK9 a \u00e9t\u00e9 bien tol\u00e9r\u00e9 et a provoqu\u00e9 beaucoup moins d\u2019effets ind\u00e9sirables de nature musculo-squelettique qu\u2019une statine pendant le traitement."}